Scientific Director, Lygature & The European Lead Factory
Ton Rijnders holds a PhD in molecular biology. He joined Organon in 1986. In 2003 Ton moved to the position of Vice President Research at Organon. In this position he had responsibility for a wide portfolio of discovery and preclinical development projects and for an extensive portfolio of collaborations in Europe and the USA. After the acquisition of Organon by Schering-Plough in 2007, Ton was appointed VP Discovery and Site Head Oss within the Schering-Plough Research Institute. He represented Schering-Plough at the Research Directors Group of EFPIA that has responsibility for the interactions with the European Commission. He continued to head Discovery in Oss within the Merck Research Labs after the merger of Merck with Schering-Plough until September 2011. He was one of the founding fathers of TI Pharma, a public private partnership in drug discovery which manages a portfolio of over 50 consortia with a total investment of around 300 m€. As of November 2011 Ton has taken up responsibility as Scientific Director at TI Pharma and as of January 1, 2016 as Scientific Director at Lygature after the merger of CTMM and TI Pharma. In addition, from January 2013 onwards Ton is also Head of the European Screening Centre, part of the IMI European Lead Factory.